Factors influencing therapeutic efficacy of denosumab against osteoporosis in systemic lupus erythematosus
Authors' conclusion
Our study suggests that denosumab is an effective treatment option for osteoporosis in patients with SLE. The therapeutic efficacy of denosumab can be predicted by baseline BMD values, SLEDAI-2K scores and hydroxychloroquine use.
Study context
- Population
- Patients with SLE with osteoporosis initiating denosumab, January 2016–December 2023
- Participants
- 166 patients
- Outcome
- Change in T-score and areal BMD at lumbar spine, total hip and femur neck from denosumab initiation
- Follow-up
- 12 months
Methodological detailssingle-group, correlation analysis, multiple linear regression
- Single-group
- Correlation analysis
- Multiple linear regression
Main finding
As reported in the abstract
BMD and bone turnover markers vs baseline
- Denosumab significantly increased bone mineral density (BMD) and decreased bone turnover markers at 12 months vs baseline
Observational data: associations, not effects.
Further findings
Correlates and predictors of BMD improvement · 12 months
- Significant negative correlation of BMD improvement with SLEDAI-2K score, HCQ use, prior osteoporosis treatment and baseline BMD
- BMI and c-telopeptide of collagen type 1 levels positively correlated with BMD improvement
- Higher baseline BMD, SLEDAI-2K scores and HCQ use were significant predictors of attenuated BMD improvement
Original publication
Factors influencing therapeutic efficacy of denosumab against osteoporosis in systemic lupus erythematosus. Lupus Sci Med. Published 22 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →